Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.
Lee. Edwin E; Burgess. Kailynd K
Key Findings
- IV BPC‑157 (up to 20 mg) did not alter biomarkers of heart, liver, kidney, thyroid, or glucose in two participants.
- No side effects or adverse events were reported during or after the infusions.
- The study was limited to two healthy adults, each of whom had prior IV exposure to BPC‑157.
Practical Outcomes
- For biohackers considering IV BPC‑157, this small study suggests that doses up to 20 mg appear safe in healthy adults, but the evidence is very limited. Use the same infusion rate (1 hour in 250 ml saline) and monitor basic labs before and after. Larger studies are needed before this can be considered a reliable protocol.
Summary
A tiny pilot study gave two healthy adults an IV dose of BPC‑157 (10 mg one day, 20 mg the next) and found no changes in heart, liver, kidney, thyroid or blood sugar labs and no side effects, suggesting the peptide is well‑tolerated at these levels.
Abstract
For years, the peptide Body Protection Compound 157 (BPC-157) has been used to treat partial muscle or tendon tears. Few studies on humans have been published, with none on the intravenous use of BPC-157 in humans. This IRB-approved study was conducted to assess whether intravenous BPC-157 is safe in humans. Baseline blood work and vital signs were obtained from 2 participants before and after each infusion. On day 1, 10 mg of BPC-157 in 250 cc of normal saline was infused over one hour. On day 2, fasting blood work was repeated, vital signs were recorded, and 20 mg of BPC-157 in 250 cc of normal saline was infused over one hour. On day 3, fasting blood work and vital signs were repeated. Patients were questioned about any side effects at each appointment. This study was performed at a private clinic in Florida. Two patients participated: a 58-year-old Asian male and a 68-year-old Caucasian female, each of whom had received intravenous BPC-157 before this trial. The infusions of BPC-157 resulted in no measurable effects on the tested biomarkers of the heart, liver, kidneys, thyroid, or blood glucose levels. The BPC-157 peptide infusion was tolerated, with no side effects reported. Intravenous infusion of up to 20 mg of BPC-157 in 2 healthy adults showed no adverse effects and was well-tolerated. The results of this pilot study showed the safety of BPC-157 in humans. Future studies are also needed to confirm the safety of intravenous BPC-157 in humans.
Study Information
pubmed
2025